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undergoing transapical aortic valve implantation: Results from the
Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA)Augusto D’Onofrio, MD,a Paolo Rubino, MD,b Melissa Fusari, MD,c Loris Salvador, MD,d
Francesco Musumeci, MD,e Mauro Rinaldi, MD,f Ettore O. Vitali, MD,g Mattia Glauber, MD,h
Roberto Di Bartolomeo, MD,i Ottavio R. Alfieri, MD,j Elvio Polesel, MD,k Marco Aiello, MD,l
Riccardo Casabona, MD,m Ugolino Livi, MD,n Claudio Grossi, MD,o Mauro Cassese, MD,p
Aniello Pappalardo,MD,q Tiziano Gherli, MD,r Guglielmo Stefanelli, MD,s Giuseppe G. Faggian,MD,t and
Gino Gerosa, MDaFrom th
Cardi
Italy;
IRCC
Hospi
Rome
ment
ment
Depa
of Ca
Surge
IRCC
Maur
Miser
S. Cr
768Objective: The aim of this study was to assess clinical and hemodynamic outcomes of transapical aortic valve
implantation (TA-TAVI) in patients enrolled in the Italian Registry of Trans-Apical Aortic Valve Implantation
(I-TA).
Methods: From April 2008 until November 2010, 504 patients from 20 Italian centers were enrolled in the I-TA
registry. Mean logistic EuroSCORE and Society of Thoracic Surgeons score were 24% 16% and 11% 4%,
respectively. Mean follow-up was 9.2 6.5 months (range, 1-26 months). Outcomes were analyzed according to
intraoperative complications, procedural volume (high-volume centers,>20 cases; low-volume centers,<20
cases) and learning curve (first 50% cases vs second 50% cases of each center).
Results:All-cause overall mortality was 8.3% (42 patients). Device success was 99% (500/504 patients). Intra-
operative severe complications occurred in 24 (4.8%) patients. Overall 2-year survival was 71.5%  6.2%. At
discharge, peak and mean gradients were 16.4  11.2 and 8.7  4.1 mm Hg, respectively, and effective orifice
area was 1.67 cm2. These values remained stable at 3, 6, and 12months after surgery. Independent risk factors for
mortality after TA-TAVI were as follows: New York Heart Association class III and IV (odds ratio [OR], 4.43;
95% confidence intervals [CI], 1.28-15.40; P ¼ .02); logistic EuroSCORE greater than 20 (OR, 1.83; 95% CI,
1.02-3.29; P¼ .04); creatinine concentration greater than 200 mmol/L (OR, 2.56; 95% CI, 1.07-6.15; P¼ .03),
and intraoperative complications (OR, 5.80; 95% CI, 2.68-12.55; P<.001). There were no significant differ-
ences in outcomes between high- and low-volume centers and between the first and the second 50% of cases.
Conclusions: TA-TAVI represents a safe and effective alternative treatment for patients who are inoperable or at
high risk for surgery. The occurrence of an intraoperative complication significantly affects survival. Procedural
volume and learning curve have no impact on patient survival. (J Thorac Cardiovasc Surg 2011;142:768-75)Although surgical aortic valve replacement (SAVR) re-
mains the treatment of choice in patients with severe sym-
ptomatic aortic valve stenosis (SSAVS), recent data
strengthen the role of transcatheter aortic valve implanta-
tion (TAVI) as an alternative treatment in high-risk or inop-
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Abbreviations and Acronyms
CI ¼ confidence intervals
I-TA
registry
¼ Italian Registry of Trans-Apical
Aortic Valve Implantation
MPG ¼ mean transvalvular pressure gradient
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PPG ¼ peak transvalvular pressure gradient
SAVR ¼ surgical aortic valve replacement
SSAVS ¼ severe symptomatic aortic valve
stenosis
STS ¼ Society of Thoracic Surgeons
TAVI ¼ transcatheter aortic valve
implantation
TA-TAVI ¼ transapical transcatheter aortic valve
implantation
TF-TAVI ¼ transfemoral transcatheter aortic
valve implantation
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great majority of these reports include mixed transapical
(TA-TAVI) and transfemoral (TF-TAVI) patient popula-
tions. The Italian Registry of Trans-Apical Aortic Valve Im-
plantation (I-TA registry) is an independent, prospective,
spontaneous multicenter registry that includes all TA-
TAVI procedures performed in Italy since this procedure be-
came available in 2008. The aim of this study was to report
clinical and hemodynamic results after TA-TAVI in patients
included in the I-TA registry, as well as to evaluate the im-
pact of intraoperative complications, learning curve, and
procedural volume on patient outcomes.PATIENTS AND METHODS
I-TA Registry
We analyzed data of 504 patients with SSAVS enrolled in 20 Italian car-
diac surgery centers from April 2008 to September 2010. Details about the
number of patients enrolled in each center and the time period are provided
in Appendix 1. Data were collected at each study site and then sent (ano-
nymized) to the University of Padova for storage and analysis. The study
was approved by the ethics committee and patient informed consent was
always collected. We included in the analysis all patients who received
a TA-TAVI since the beginning of the TAVI program of each center to ob-
tain a ‘‘real-world,’’ ‘‘all-comers’’ experience.
Procedure
All procedures were performed with the patient under general anesthe-
sia according to the usual technique.3 All patients received a Sapien
pericardial bioprosthesis (Edwards Lifesciences, Irvine, Calif) via a trans-
apical approach. A 23-mm valve was implanted in the presence of an aortic
annulus diameter of 21 mm or less, whereas a 26-mm valve was implanted
in annuli larger than 21 mm. In the case of an annulus measuring 21.5 mm,
the decision onwhether to implant a 23-mmor a 26-mmvalvewas based on
the amount and distribution of calcium and on root dimensions. Valve size
29 was not yet available during the study period. Indications for TAVI wereThe Journal of Thoracic and Caas follows: (1) SSAVS (with or without aortic valve regurgitation) with an
aortic valve area less than 0.8 cm2 and mean transaortic gradient greater
than 40 mm Hg, logistic EuroSCORE greater than 20%, and Society of
Thoracic Surgeons (STS) score greater than 10%; (2) ascending porcelain
aorta. Patients were excluded if the diameter of the aortic annulus was less
than 18 mm or more than 25 mm or if their postprocedural life expectancy
was less than 1 year. We did not consider specific age limits for TAVI. Each
case was discussed by the local ‘‘TAVI team,’’ which included a cardiac
surgeon, an interventional cardiologist, and an anesthesiologist. Inasmuch
as the vast majority of these centers follow a ‘‘transfemoral first’’ policy,
the transapical approach was chosen in patients with severe disease of
the aortoiliac–femoral arterial vessels or in patients with small peripheral
vessels. The role of the anesthesiologist was mainly related to the respira-
tory aspect of patients: in case of severe pulmonary insufficiency, a transfe-
moral procedure with the patient awake was always considered the best
option. The procedures were performed by the ‘‘TAVI team’’ in a conven-
tional operating room with a portable C-arm fluoroscopic system (10 cen-
ters), in a fully equipped hybrid operating room (3 centers), or in the
catheterization laboratory (7 centers).
Follow-up
Patients underwent clinical and echocardiographic assessment at the
study site before the operation, at hospital discharge, 3 and 6 months after
TA-TAVI, and every 6 months thereafter.
Data and Definitions
Preoperative risk factors were defined according to the EuroSCORE
classification (http://www.euroscore.org/euroscore_scoring.htm). Device
success was defined, according to the Valve Academic Research Consor-
tium definitions, as follows: (1) successful access, delivery, and deploy-
ment of the device and successful retrieval of the delivery system; (2)
correct position of the device in the proper anatomic location; (3) intended
performance of the prosthetic heart valve (aortic valve area>1.2 cm2 and
mean aortic valve gradient<20 mm Hg or peak velocity<3 m/s, without
moderate or severe prosthetic valve regurgitation); (4) only 1 valve im-
planted in the proper anatomic location. Thirty-day mortality was defined
as ‘‘all-cause’’ and ‘‘cardiovascular’’ according to the Valve Academic Re-
search Consortium definitions.4 We were not able to use the Valve Aca-
demic Research Consortium definitions for echocardiographic data
inasmuch as these were published in January when all echocardiographic
examinations had already been performed. Immediate postoperative aortic
regurgitation was evaluated, after valve deployment and removal of the
transaortic guidewire, using both transesophageal and aortic angiography.
The echocardiographic measurements were performed according to the
current recommendations.5 Peak (PPG) and mean (MPG) transvalvular
pressure gradients were derived by using the modified Bernoulli equation
and the effective orifice area was calculated with the continuity equation.6
The angiographic evaluation of aortic regurgitation was made according to
the method described by Sellers and colleagues.7 Aortic regurgitation was
classified as absent, trivial (1þ/4þ), mild (2þ/4þ), moderate (3þ/4þ), or se-
vere (4þ/4þ)8 on the basis of data obtained from both the diagnostic proce-
dures. The impact of procedural volume on patient outcomes was analyzed
by comparing overall survival at follow-up between patients operated on in
high-volume and low-volume centers. High- and low-volume centers were
defined according to the number of total procedures performed: ‘‘high vol-
ume’’ when therewere more than 20 procedures; ‘‘low volume’’ with fewer
than 20 procedures. The impact of learning curve on patient outcomes was
analyzed by comparing the overall survival of the first 50% versus the sec-
ond 50% of patients for each center.
Statistical Analysis
Continuous data are expressed by mean  1 standard deviation or me-
dian as appropriate. Categorical data are summarized by reporting the per-
centages. Cumulative survival was estimated using the Kaplan-Meierrdiovascular Surgery c Volume 142, Number 4 769
TABLE 1. Preoperative characteristics in 504 patients
Characteristics No. of patients* %
Logistic EuroSCORE (%) 26.3  13.8
STS score (%) 11  4
Age (y) 81.2  6.5
Acquired Cardiovascular Disease D’Onofrio et al
A
C
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variables were compared by the Mann-Whitney test. Survivals were com-
pared by the log–rank test. A stepwise logistic regression analysis was used
to determine the predictive factors of late mortality. Statistical analyses
were performed using STATISTICA software (release 9.1; Statsoft Inc,
Tulsa, Okla).LVEF (%) 52.4  13.6
Aortic peak gradient (mm Hg) 74.7  23.3
Aortic mean gradient (mm Hg) 47.4  15.4
Aortic valve area (cm2) 0.53  0.18
Creatinine (mg/dL) 1.3  0.8
Female sex 306 60.7
Arterial hypertension 402 79.8
Diabetes 139 27.6
NYHA class III-IV 419 83.1
COPD 173 34.3
Dialysis 24 4.8
Previous cardiac surgery 83 16.5
Severe ascending aortic
calcifications
108 21.4
Mitral regurgitation (3þ/4þ) 41 8.1
Peripheral vascular disease 229 45.4
Neurologic dysfunction 39 7.7
Atrial fibrillation 119 23.6RESULTS
Patient Population
Preoperative characteristics are summarized in Table 1.
Mean age was 81  6 years (range, 44-95 years), and
60.7% were female. The 44-year-old patient was sched-
uled for TAVI for an extremely severe case of porcelain
aorta derived from previous chest irradiation owing to
a history of malignant lymphoma. Mean logistic Euro-
SCORE was 24%  16% (range, 7%-87%) and mean
STS score was 11%  4% (range, 3%-45%). Previous
percutaneous coronary intervention was performed in
114 (22.6%) patients and a previous cardiac operation
was performed in 83 (16.5%). A total of 419 (83.1%) pa-
tients were in New York Heart Association (NYHA) func-
tional class III-IV.Pulmonary hypertension 49 9.7
History of coronary artery disease 254 50.4
Previous PCI 111 22
Previous CABG 72 14.3
Untreated 71 14.1
STS, Society of Thoracic Surgeons; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association; COPD, chronic obstructive pulmonary disease; PCI,
percutaneous coronary intervention; CABG, coronary artery bypass grafting. *The
number of patients begins with the category ‘‘female sex.’’Early Results
Valve sizes 23 and 26 were used in 183 (36.3%) and 321
(63.7%) patients, respectively. Device success was 99%
(500 patients). In 4 patients device success was not achieved
for the following reasons: in 3 patients the insertion of a sec-
ond valve was required because of malpositioning of the
first prosthesis and in 1 patient the transapical valve embol-
ized in the left ventricle and the patient underwent conven-
tional SAVR. A total of 24 (4.8%) severe intraoperative
complications occurred. Causes of intraoperative complica-
tions were as follows:
 Emergency cardiopulmonary bypass or extracorporeal
membrane oxygenation for refractory cardiogenic shock
was required in 10 (1.9%) patients
 Cardiopulmonary resuscitation for severe hemodynamic
impairment after valve deployment was performed in 5
(1%) patients
 Coronary artery occlusion requiring percutaneous coro-
nary intervention with or without coronary stenting oc-
curred in 5 (1%) patients
 Severe intraoperative bleeding occurred in 4 (0.8%)
patients
All-cause 30-day mortality was 8.3% (42 patients). Car-
diovascular 30-day mortality was 6.7% (34 patients).
Causes of overall 30-day mortality were as follows: cardio-
genic shock/multiorgan failure in 15 patients, sepsis in 8
patients, major ventricular arrhythmia in 5 patients, mesen-
teric ischemia in 6 patients, stroke in 6 patients, and severe
hemorrhage in 2 patients.770 The Journal of Thoracic and Cardiovascular SurgContinuous venovenous hemofiltration for class F acute
kidney injury (according to the Risk, Injury, Failure, Loss,
End-stage kidney disease [RIFLE] classification)9 was re-
quired in 31 (6.1%) patients.
Trivial and mild aortic regurgitation (1-2þ/4þ), mainly
owing to perivalvular leak at hospital discharge, was found
in 138 (29.9%) and 40 (8.6%) patients, respectively. Per-
manent pacemaker implantation was required in 27
(5.3%) patients. Incidence of major stroke was 3% (15 pa-
tients). Incidence of periprocedural acute myocardial in-
farction was 1.6% (8 patients). Median intensive care unit
stay was 2 days (quartiles 1-3) and mean hospital stay
was 9  4 days.Follow-up
Follow-up was 100% complete. Mean follow-up was 9.2
 6.5 months (range, 1-26 months). One-year overall
Kaplan-Meier survival was 81.4% 2.2%. Two-year over-
all Kaplan-Meier survival was 71.5%  6.2% (Figure 1).
Late mortality occurred in 34 patients. Cardiovascular late
mortality occurred in 22 patients. Causes of late mortality
were congestive heart failure in 12 patients, sepsis/ery c October 2011
FIGURE 1. Two-year Kaplan-Meier overall survival of 504 patients after
transapical aortic valve implantation (TAVI).
FIGURE 3. Kaplan-Meier overall survival at 18 months of the first 50%
and the second 50% of patients of each center. TAVI, Transapical aortic
valve implantation.
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brovascular accident in 5 patients, cancer in 3 patients,
and liver cirrhosis in 1 patient.
Kaplan-Meier overall survival of patients operated on in
high- and low-volume centers at 18 months was 78.3% 
9.4% and 73.9% 8.1%, respectively (P ¼ .3) (Figure 2).
Kaplan-Meier overall survival at 18 months of the first
50% and the second 50% of patients of each center was
77.2%  7.3% and 81.5%  7.8%, respectively
(P ¼ .9) (Figure 3). The variable with a significant impact
on overall survival at follow-up was the occurrence of anFIGURE 2. Kaplan-Meier overall survival of patients operated on in high-
and low-volume centers at 18 months. TAVI, Transapical aortic valve im-
plantation.
The Journal of Thoracic and Caintraoperative complication. Kaplan-Meier overall survival
at 18 months was significantly lower in patients who had
an intraoperative complication (37.3%  4.6%) when
compared with patients who did not have any complica-
tion (80.7%  8.6%) (P<.001) (Figure 4).The following
variables were found to be risk factors for 30-day mortal-
ity at the univariate analysis: age older than 85 years,
NYHA class III-IV, logistic EuroSCORE greater than
20%, creatinine levels greater than 200 mmol/L, preoper-
ative dialysis, and intraoperative complications. Multivar-
iate analysis identified the following as independent
predictors for mortality: NYHA class III and IV (odds ra-
tio [OR], 4.43; 95% confidence intervals [CI], 1.28-15.40;
P ¼ .02); logistic EuroSCORE greater than 20% (OR,
1.83; 95% CI, 1.02-3.29; P ¼ .04); creatinine greater
than 200 mmol/L (OR, 2.56; 95% CI, 1.07-6.15;
P ¼ .03), and intraoperative complications (OR, 5.80;
95% CI, 2.68-12.55; P< .001). There were no cases of
structural valve deterioration and endocarditis of the aortic
bioprosthesis during follow-up. A significant NYHA class
improvement was observed at follow-up (16% of patients
were in NYHA class III-IV at follow-up vs 83.1% preop-
eratively; P < .001). Hemodynamic data are shown in
Table 2. At discharge, PPG and MPG were 16.4  11.2
mm Hg and 8.7  4.1 mm Hg, respectively. Effective or-
ifice area was 1.67 cm2 at discharge. A significant reduc-
tion of PPG and MPG from the preoperative to the
postoperative period was found (P<.001); these values re-
mained stable at 3, 6, and 12 months after surgery. Fur-
thermore, a significant increase of aortic valve area wasrdiovascular Surgery c Volume 142, Number 4 771
FIGURE 4. Kaplan-Meier survival at 18 months of patients with and
without intraoperative complications. TAVI, Transapical aortic valve im-
plantation.
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aortic regurgitation were found.
COMMENT
The I-TA registry is a prospective registry reporting the
entire Italian TA-TAVI experience. The registry is spontane-
ous, prospective, and independent from industries. These
characteristics allow an objective evaluation of ‘‘real
world’’ outcomes without bias deriving from patient selec-
tion, thus providing a paramount picture of all TA-TAVI
patients operated on during the past 3 years in Italy. Other
already existing TAVI registries have different characteris-
tics. The German and the Belgian registries8,10 include
Edwards Sapien and Medtronic CoreValve (Medtronic,
Inc, Minneapolis, Minn) and take into account transapical
and transfemoral approaches; the SOURCE registry11 in-
cludes only selected European centers and analyzes trans-
apical and transfemoral Sapien valve procedures only
during the first year after commercialization. The CanadianTABLE 2. Echocardiographic data
Valve size
(no. of patients)
Preoperative* Discharge*
23 (175) 26 (306) 23 (139) 26 (254) 23
PPG (mm Hg) 87  25 80  22 22  10 23  12 24
MPG (mm Hg) 53  17 50  14 11  4 10  4 11
EOA (cm2) 0.5  0.2 0.7  0.3 1.7  0.5 1.8  0.7 1.6
PPG, Peak prosthesis gradient; MPG, mean prosthesis gradient; EOA, effective orifice area
lowing assessments. No significant differences among postoperative examinations.
772 The Journal of Thoracic and Cardiovascular Surgexperience12 analyzes transapical and transfemoral proce-
dures performed using the Edwards Sapien valve; it is
very complete and exhaustive but only 6 centers are
involved. The Italian CoreValve registry includes only
TF-TAVI patients treated with the Medtronic CoreValve re-
valving system.13
The analysis of I-TA data showed that TA-TAVI during
the first 3 years of experience in Italy was carried out with
a 30-day all-cause mortality of 8.3% and with an overall
2-year survival of 71%. Variables predicting 30-day mor-
tality after TA-TAVI were NYHA class III-IV, logistic
EuroSCORE greater than 20, creatinine levels greater
than 200 mmol/L, and the occurrence of intraoperative
complications. Thirty-day mortality was lower than ex-
pected (predicted mortalities were 26% and 11% with lo-
gistic EuroSCORE and STS score, respectively; observed/
expected [STS] mortality ¼ 0.75) and consistent with the
aforementioned registries (SOURCE, 10.3%; Germany,
8.2%; Belgium, 12%; Canada, 10.4%). Furthermore,
this is a mixed population that includes inoperable pa-
tients and high-risk patients. This is an important factor
if we compare I-TA 30-day mortality (8.3%) with the ex-
cellent results observed in the recently presented results
of the PARTNER A trial (http://my.americanheart.org/
idc/groups/ahamah-public/@wcm/@sop/@scon/documents/
downloadable/ucm_425332.pdf). PARTNER A investiga-
tors reported an overall all-cause 30-day mortality, de-
rived by an intention-to-treat analysis, of 3.4%, which
is the lowest ever presented. Intention-to-treat 30-day
mortality of the PARTNER A TA-TAVI subgroup was
3.8%; however, the as-treated mortality rate accounts
for 8.7%, similar to I-TA and to other registries. The
PARTNER trial,1 as well as all prospective randomized
studies, has strict inclusion and exclusion criteria to guar-
antee homogeneity among groups. However, on the other
hand, these create a bias between ‘‘trial population’’ and
‘‘real world.’’ It is important to notice that all centers in-
cluded in the I-TA registry have a combined transapical
and transfemoral program with a ‘‘transfemoral-first’’
policy. This means that the vast majority of patients in-
cluded in our registry had undergone a multidisciplinary
selection process at the study site that was in favor of
a transapical approach mainly for peripheral artery inac-
cessibility (stenosis or small caliber). Thus, preoperative
risk profile of these patients was high not only for3 mo* 6 mo* 12 mo*
(112) 26 (187) 23 (87) 26 (141) 23 (51) 26 (78)
 10 23  11 24  9 22  12 28  8 24  12
 5 9  3 11  4 9  3 14  6 10  5
 0.5 1.7  0.7 1.5  0.5 1.7  0.9 1.5  0.6 1.9  0.8
. *Statistically significant difference (P<.001) between preoperative and all the fol-
ery c October 2011
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disease. The access-related issue in TAVI literature is
still unsolved. Inasmuch as all studies are based on
a ‘‘transfemoral-first’’ policy, transapical patients have
higher preoperative risk scores and worse early outcomes
than transfemoral patients.11,12 In our registry, the
incidence of severe intraoperative bleeding related to the
transapical approach was only 0.8% (4 patients), which
is much lower than the 16.2% of major vascular
complications reported in the PARTNER B trial.1 Unfor-
tunately, the PARTNER A, which is the only prospective
randomized trial currently available, did not have suffi-
cient statistical power to compare TA-TAVI with either
SAVR or TF-TAVI. In other words, there is no evidence
that TA-TAVI should be performed as a ‘‘second-choice’’
treatment whenever TF-TAVI is not feasible. The cardiac
surgery community should keep this issue in mind when
discussing TAVI patients. Access choice should be based
not only on the feasibility of a peripheral approach but
above all on the specific clinical characteristics of each
patient.
The impact of intraoperative complications on patient
outcomes is another important issue that arises from data
analysis. In our experience it was a strong determinant of
30-day mortality with negative impact on late survival: 10
(41.7%) of 24 patients with a severe intraoperative compli-
cation died at 30 days; 25% of 30-day deaths occurred
in patients who had an intraoperative complication;
20-month survival of these patients was only 37%. This
finding partially confirms what was already described by
Rodes-Cabau and associates,12 who indentified the need
for periprocedural hemodynamic support as an independent
risk factor for 30-day mortality (OR, 6.84). In view of the
strong impact of intraoperative complications on patient
early and late outcomes, we should direct all our efforts to-
ward preventing and effectively managing such occurrence.
Prevention can be achieved by careful patient selection, ad-
equate procedural planning (access choice, valve sizing),
and execution. The successful management of complica-
tions needs a strict safety policy whose main feature should
be the multidisciplinary approach to the TAVI program. Ye
and associates,14 in their series of 71 consecutive TA-TAVI
patients, reported 5 early deaths in the initial 15 patients
(mortality rate, 33%) of their experience. They also re-
ported a significant improvement in terms of procedural
success, malposition, and early mortality in the second
half of their TF-TAVI experience.15 This is confirmed by
Himbert and colleagues,16 who found early experience to
be the only significant predictor of mortality . They com-
mented that such finding emphasized the role of patient se-
lection, equipment, and experience. In our large multicenter
series of patients, we did not find learning curve or proce-
dural volume to be significant factors affecting outcomes.
This could be related to the accurate initial experience ofThe Journal of Thoracic and Caeach center, which included center start-up phase with sim-
ulator use for each operator (physicians, technicians, and
nurses), preoperative case selection and discussion with
an experienced operator (proctor), equipment standardiza-
tion according to manufacturer guidelines, and proctor-
assisted procedures. Echocardiographic examinations
found Sapien valve PPG and MMG 16.4  11.2 mm Hg
and 8.7  4.1 mm Hg, respectively, at discharge. These
values are consistent with those reported in the PARTNER
trial1 and in other reports.11,17,18
This study has several limitations. The number of pa-
tients operated on in each center was not homogeneous,
ranging from 5 to 88. We did not have data about compara-
ble SAVR and TF-TAVI populations. Echocardiographic
examinations were performed by different physicians using
different machines.
In conclusion, I-TA registry data demonstrate that in
high-risk or inoperable patients with SSAVS, TA-TAVI is
a safe and satisfactory therapeutic option inasmuch as it
can be performed with low 30-day mortality, good 2-year
survival, and with low incidence of complications related
to the apical approach. Survival is not affected by either
learning curve or procedural volume. NYHA class, high
EuroSCORE values, high creatinine levels, and intraopera-
tive complications were identified as independent risk fac-
tors for 30-day mortality. Longer follow-up is warranted
to evaluate long-term results and to reach time points
when degeneration and valve-related adverse events are
more likely to occur.References
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DDiscussion
Dr Lars G. Svensson (Cleveland, Ohio).Dr D’Onofrio has pre-
sented one of the largest series on the transapical approach with
good results. The 8.3% hospital mortality and 3% major stroke
rate for these high-risk patients, with a significant atherosclerotic
load, is remarkably good. Having been involved in the original
transapical approach research with Drs Mike Mack, Todd Dewey,
Thomas Walther, Fred Mohr, John Webb and his team, and from
the Edwards team, Mike Mussallem, Larry Woods, Jill Trekell,
Jody Akins, and Mark Dehdastian starting in 2004, it is very grat-
ifying, despite our early hiccups, to see how the technology has
matured and improved.
It is incumbent on me to compare this presentation with the
results from the PARTNER A study, presented at the American
College of Cardiology meeting by our upcoming president, Craig
Smith. In that study, with the transfemoral approach as the de-
fault approach, if access was possible, as in your Italian study,
transapical patients had more cerebrovascular disease, carotid
endarterectomies, previous coronary artery bypass grafting, per-
cutaneous coronary intervention, porcelain aorta, atrial fibrilla-
tion, obviously peripheral vascular disease, and more severe
aortic valve stenoses, all of which are evidence of greater athero-
sclerotic load and also risk for death and stroke. The mortality
and stroke rates in the PARTNER A study were equivalent to
the TA arm; in other words, open aortic valve replacement was
equivalent to the TA-TAVI.
Given that in Italy and the United States the transfemoral ap-
proach is the default choice for patients but has not been compared
with the transapical approach, what is the likelihood in Italy that
you could do a prospective randomized trial comparing transfe-
moral versus transapical and also including the new approach,
the transaortic approach? Do you have any registry data yet for
Italy for the transaortic procedure even though the current device
was neither designed for this nor is ideal for the transaortic
approach?
Clearly we need to aim to reduce the stroke rate to the superb
low risk of 1.4% noted in the open aortic valve replacement control
group in the transfemoral part of the PARTNER A trial. Have you
had the opportunity to try any of the new stroke filter or carotid
protection devices, including using the EMBOL-X filter (Edwards
Lifesciences), particularly for the transaortic procedure?The Journal of Thoracic and CaDr D’Onofrio. Dr Svensson, thank you for your comments and
for these questions.
The great majority of centers that participated in this study fol-
lowed a transfemoral-first policy. This means that about 90% of
these patients underwent screening for a transfemoral procedure
and, since they were not considered suitable for a transfemoral ap-
proach, they went for a transapical valve implantation. Conse-
quently these patients had a higher risk profile in terms of
peripheral arterial disease, stroke, and mesenteric ischemia. Actu-
ally, we observed a low incidence of stroke and a low incidence of
access-related complications, for example, major bleeding from
the left ventricular apex. If we compare these results with the in-
cidence of major vascular complications that were reported in
the SOURCE and in the PARTNER trial that ranged from 10%
to 15%, the result is that to date there is no strong evidence that
supports the transfemoral-first policy. Unfortunately, the PART-
NER trial was not powered enough to compare the transfemoral
versus the transapical approach. I think that all cardiac surgeons
should be well aware of this problem when discussing TAVI cases
with cardiologists.
We do not have to necessarily go straight for a transfemoral ap-
proach first and then, only if the patient is not suitable, choose the
transapical technique, sincewe do not have evidence to support this
strategy. I think that we should determine the best approach for ev-
ery single patient. This registry gave us the opportunity to create
a good network of centers that perform transapical procedures.
The idea of a prospective randomized trial is excellent, and I
hope that we will be able to do that in the near future.
Dr Svensson. Just to address that, there are plans ahead to do
a European prospective randomized trial. You might want to dis-
cuss this with Thomas Walther. Obviously in some centers it
will be difficult, but for those who have the option of either proce-
dure, you might want to talk to him. I understand there are plans at
Edwards to finance this. So I would encourage those centers in
Italy that can to get involved with a prospective randomized trial.
Dr D’Onofrio. I will discuss this issue with my Italian col-
leagues. Thank you.
Regarding your questions about the EMBOL-X filters and
transaortic approach, we do not have data in this registry about
transaortic procedures, and we did not collect data about the use
of aortic filters to prevent embolic events.rdiovascular Surgery c Volume 142, Number 4 775
